$7.7M
2 filings since 2024 · latest Other filed
Lapix Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Cambridge, MA, dedicated to developing innovative oral therapeutics that restore immune system function for patients with autoimmune diseases. Through a patient-centric approach, Lapix Therapeutics is pioneering treatments that enhance the body's natural immune tolerance.
What sets it apart
Lapix stands out by focusing on immune system restoration without broadly suppressing immunity, providing a gentler alternative to existing autoimmune therapies.
LPX-TI641 is an oral small-molecule drug developed to target the T cell/transmembrane, immunoglobulin, and mucin (Tim) family of receptors. It is designed to restore the body’s natural immune tolerance in patients with autoimmune diseases.
